Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
BIENAIME JEAN JACQUES
   2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [BMRN] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last)
(First)
(Middle)
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE		 3. Date of Earliest Transaction (Month/Day/Year)
12/05/2013
(Street)

NOVATO, CA 94949		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/05/2013(1) 12/05/2013 A   5,000 A $ 12.99 55,740 I Shares Held in Bienaime Family Trust (2)
Common Stock 12/05/2013(1) 12/05/2013 S   5,000 D $ 69.6969 (3) 50,740 I Shares held by Bienaime Family Trust (2)
Common Stock               10,000 I Held in irrevocable trust for Guillaume Bienaime (4)
Common Stock               10,000 I Held in irrevocable trust for Pierre Bienaime (4)
Common Stock               10,000 I Held in irrevocable trust for Paul Bienaime (4)
Common Stock               10,000 I Held in irrevocable trust for Marc Bienaime (4)
Common Stock               20,000 I Held in irrevocable trust for Aurelie Mitsuki Bienaime and Anais Kimiko (4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy Common Stock) $ 12.99 12/05/2013 12/05/2013 M     5,000 11/11/2006(5) 05/10/2016 Common Stock 5,000 $ 0 85,000 (6) I Shares held by Bienaime Family Trust (2)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949		   X     Chief Executive Officer  

Signatures

 /s/ Laura Randall Woodhead, Attorney-in-Fact   12/09/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Transaction made pursuant to a Rule 10b5-1 rdinplan executed on February 26, 2013.
(2) The reporting person and his spouse act as trustees for the Bienaime Family Trust.
(3) The price in column 4 is a weighted average price. The price actually received ranged from $69.35 to $70.14. The reporting person will provide to the issuer, any security holder of the issuer, ot th SEC staff, upon request, information regarding the number of shares sold at rach price within the range.
(4) The reporting person's spouse is trustee of each child's trust.
(5) Original option grant vests 6/48th on November 11, 2006, and 1/48th on the 11th day of every month thereafter
(6) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.